• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Precigen Inc.

    9/19/25 8:55:36 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PGEN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 20)


    PRECIGEN, INC.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    46122T102

    (CUSIP Number)


    Third Security, LLC
    1881 Grove Avenue, Attention: April D. Jones
    Radford, VA, 24141
    5406337900


    John Owen Gwathmey, Esq.
    Troutman Pepper Locke Building, 1001 Haxall Point
    Richmond, VA, 23219
    8046971239


    David I. Meyers, Esq.
    Troutman Pepper Locke Building, 1001 Haxall Point
    Richmond, VA, 23219
    8046971239


    Troutman Pepper Locke, LLP
    Troutman Pepper Locke Building, 1001 Haxall Point
    Richmond, VA, 23219
    8046971239

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    09/17/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    46122T102


    1 Name of reporting person

    RANDAL J. KIRK
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    146,295,359.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    146,295,359.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    146,295,359.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    39.4 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    The indicated amount of Common Stock beneficially owned by Mr. Kirk assumes the full conversion of (i) 25,000 shares of Preferred Stock, as that term is defined herein (ii) 906,512 Options to Purchase Common Stock, which are fully vested and exercisable at the discretion of Mr. Kirk, and (iii) 16,666,667 Warrants to Purchase Common Stock, which are fully vested and exercisable at the discretion of Mr. Kirk.


    SCHEDULE 13D

    CUSIP No.
    46122T102


    1 Name of reporting person

    R.J. KIRK DECLARATION OF TRUST
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    98,831,434.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    98,831,434.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    98,831,434.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    26.6 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    OO - trust; The indicated amount of Common Stock beneficially owned by RJ DOT assumes the full conversion of (i) 25,000 shares of Preferred Stock, as that term is defined herein and (ii) 16,666,667 Warrants to Purchase Common Stock, which are fully vested and exercisable at the discretion of Mr. Kirk.


    SCHEDULE 13D

    CUSIP No.
    46122T102


    1 Name of reporting person

    SUNSET 2020 LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    16,406,828.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    16,406,828.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    16,406,828.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.4 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    OO - limited liability company


    SCHEDULE 13D

    CUSIP No.
    46122T102


    1 Name of reporting person

    THIRD SECURITY, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    VIRGINIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    27,454,284.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    27,454,284.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    27,454,284.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    7.4 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    OO - limited liability company


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock
    (b)Name of Issuer:

    PRECIGEN, INC.
    (c)Address of Issuer's Principal Executive Offices:

    20374 Seneca Meadows Parkway, Germantown, MARYLAND , 20876.
    Item 1 Comment:
    This Amendment No. 20 (the "Amendment") amends and supplements the Statement on Schedule 13D, dated March 27, 2014 and filed on April 7, 2014, as amended by Amendment No. 1 dated December 31, 2014 and filed on January 5, 2015, by Amendment No. 2 dated May 31, 2016 and filed June 2, 2016, by Amendment No. 3 dated July 24, 2017 and filed July 26, 2017, by Amendment No. 4 dated October 16, 2017 and filed October 23, 2017, by Amendment No. 5 dated December 29, 2017 and filed on January 2, 2018, by Amendment No. 6 dated January 19, 2018 and filed January 22, 2018, by Amendment No. 7 dated July 3, 2018 and filed July 6, 2018, by Amendment No. 8 dated May 13, 2019 and filed May 15, 2019, by Amendment No. 9 dated May 24, 2019 and filed on May 24, 2019, by Amendment No. 10 dated June 6, 2019 and filed on June 10, 2019, by Amendment No. 11 dated January 1, 2020 and filed on January 6, 2020, by Amendment No. 12 dated January 31, 2020 and filed on February 4, 2020, by Amendment No. 13 dated August 11, 2020 and filed on August 13, 2020, by Amendment No. 14 dated December 17, 2020 and filed on December 21, 2020, by Amendment No. 15 dated October 6, 2022 and filed on October 7, 2022, by Amendment No. 16 dated January 27, 2023 and filed on January 31, 2023, by Amendment No. 17 dated May 2, 2024 and filed on May 3, 2024, by Amendment No. 18 dated August 9, 2024 and filed on August 13, 2024, and by Amendment No. 19 dated and filed on December 30, 2024 (the "Original Schedule 13D"), relating to the Common Stock, no par value per share (the "Common Stock"), of Precigen, Inc., formerly known as Intrexon Corporation, a Virginia corporation (the "Company"). Mr. Randal J. Kirk ("Mr. Kirk"), the R.J. Kirk Declaration of Trust, a revocable trust established by Mr. Kirk ("RJ DOT"), Third Security, LLC, a Virginia limited liability company that is controlled by Mr. Kirk ("Third Security"), and Sunset 2020 LLC, a Delaware limited liability company that is controlled by Mr. Kirk ("Sunset 2020" and, together with Mr. Kirk, the RJ DOT, and Third Security, the "Reporting Persons") are filing this Amendment to disclose (i) the receipt on September 17, 2025 of 17,385,257 shares of Common Stock by RJ DOT following the election to convert 25,000 shares of 8.00% Series A Convertible Perpetual Preferred Stock ("Preferred Stock"), which Preferred Stock was issued to RJ DOT pursuant to a Securities Purchase Agreement entered into by and between the Company and certain existing and new investors in a private placement transaction that closed on December 30, 2024 (the "Offering") and (ii) the sale of an aggregate of 5,000,252 shares of Common Stock by Kapital Joe, LLC, a Virginia limited liability company under the common control of Mr. Kirk ("Kapital Joe"), in open market transactions between September 18, 2025 and September 19, 2025.
    Item 2.Identity and Background
    (a)
    See Original Schedule 13D
    (b)
    See Original Schedule 13D
    (c)
    See Original Schedule 13D
    (d)
    See Original Schedule 13D
    (e)
    See Original Schedule 13D
    (f)
    See Original Schedule 13D
    Item 4.Purpose of Transaction
     
    Item 4 of the Original Schedule 13D is hereby amended and supplemented as follows: The information set forth in Items 3 and 6 is incorporated herein by reference. In the Offering, the Company issued 79,000 shares of Preferred Stock of the Company to certain new and existing investors, including RJ DOT, on the terms and conditions set forth in that certain Securities Purchase Agreement, filed as Exhibit 10.1 to the Company's Current Report on Form 8-K dated December 27, 2024 and filed on December 30, 2024. The Preferred Stock was convertible into shares of common stock of the Company (i) at the option of the holder at any time on or after the later of the six-month anniversary of the issue date and the date on which the issuer has, among other things, obtained shareholder approval, which requisite shareholder approval was obtained on June 26, 2025 and (ii) at an initial conversion price of approximately $1.125 per share, which conversion price was subject to upward adjustment based on the valuation of the common stock from time to time. On September 17, 2025, RJ DOT received 17,385,257 shares of Common Stock following its election to convert 25,000 shares of Preferred Stock. RJ DOT acquired these shares for investment purposes. Kapital Joe sold a total of 5,000,252 shares of Common Stock in open market transactions between September 18, 2025 and September 19, 2025, for aggregate net proceeds of approximately $18,648,905.62.
    Item 5.Interest in Securities of the Issuer
    (a)
    The responses to Items 11 and 13 of the cover pages, as well as the applicable comments thereto, to this Amendment No. 20 are incorporated herein. The percentage ownership is calculated based on 297,972,920 shares of Common Stock issued and outstanding as of August 8, 2025, as disclosed in the Company's Form S-3 Registration Statement dated and filed on August 19, 2025, increased by (i) 54,937,411 shares of Common Stock issued by the Company pursuant to the conversion of the Preferred Stock, as disclosed by the Company on its Form 8-K filed on September 17, 2025, of which Mr. Kirk received 17,385,257 shares of Common Stock issued to RJ DOT (ii) 16,666,667 shares of Common Stock issuable to Mr. Kirk upon exercise of Warrants to Purchase Common Stock, which are exercisable within sixty (60) days; (iii) 906,512 shares of Common Stock issuable to Mr. Kirk upon exercise of Options to Purchase Common Stock, which are exercisable within sixty (60) days, and (iv) 1,154,000 shares of Common Stock issued on September 12, 2025 to certain executive officers of the Company pursuant to vested Performance Stock Units, as reported by the Company in Forms 4 filed on September 16, 2025.
    (b)
    The responses to Items 7, 8, 9 and 10 of the cover pages to this Amendment No. 20 are incorporated herein.
    (c)
    Except as disclosed in the Original Schedule 13D and this Amendment No. 20, the Reporting Persons have not engaged in any transactions within the previous sixty (60) days.
    (d)
    Not applicable
    (e)
    Not applicable
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    Item 6 of the Original Schedule 13D is hereby amended and supplemented to include the responses in Item 4 above.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 1 Joint Filing Agreement, dated as of September 19, 2025, by and among Randal J. Kirk, R.J. Kirk Declaration of Trust, Sunset 2020 LLC, and Third Security, LLC.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    RANDAL J. KIRK
     
    Signature:/s/ Randal J. Kirk
    Name/Title:Randal J. Kirk
    Date:09/19/2025
     
    R.J. KIRK DECLARATION OF TRUST
     
    Signature:/s/ Randal J. Kirk
    Name/Title:Randal J. Kirk Trustee
    Date:09/19/2025
     
    SUNSET 2020 LLC
     
    Signature:/s/ Randal J. Kirk
    Name/Title:Randal J. Kirk Manager
    Date:09/19/2025
     
    THIRD SECURITY, LLC
     
    Signature:/s/ Randal J. Kirk
    Name/Title:Randal J. Kirk Managing Member
    Date:09/19/2025
    Get the next $PGEN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PGEN

    DatePrice TargetRatingAnalyst
    8/15/2025Underweight → Neutral
    Analyst
    3/22/2024Neutral → Underweight
    JP Morgan
    5/23/2023Neutral
    JP Morgan
    11/18/2022$7.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Precigen upgraded by Analyst

    Analyst upgraded Precigen from Underweight to Neutral

    8/15/25 8:13:17 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen downgraded by JP Morgan

    JP Morgan downgraded Precigen from Neutral to Underweight

    3/22/24 7:52:12 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JP Morgan initiated coverage on Precigen

    JP Morgan initiated coverage of Precigen with a rating of Neutral

    5/23/23 7:32:58 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precigen Announces Up to $125 Million Non-Dilutive Financing

    $100 million funded at close fortifies balance sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion into international markets and the pursuit of pediatric and other HPV-related indications GERMANTOWN, Md., Sept. 2, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that it has entered into a credit facility agreement with investment funds managed by Pharmakon Advisors, LP. "I am pleased to announ

    9/3/25 7:00:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

    GERMANTOWN, Md., Aug. 25, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that Precigen will participate in two upcoming virtual fireside chats hosted by Jennifer Kim of Cantor, and Swayampakula Ramakanth, PhD, of H.C. Wainwright to discuss the recent approval of the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis. Cantor Virtual Fireside ChatAugust 27, 2025, 11 AM – 12 PM ET

    8/25/25 8:05:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

    PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with RRP PAPZIMEOS received full approval from the FDA for the treatment of adults with RRP; a confirmatory clinical trial is no longer required RRP is a rare, debilitating, and potentially life-threatening disease caused by chronic HPV 6 or HPV 11 infection, which results in recurrent benign tumors in the respiratory tract; RRP affects an estimated 27,000 adult patients in the USPAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy designed to generate an immune response directed against papilloma cells expressing HPV 6/11—the firs

    8/15/25 7:00:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Thomasian Harry Jr. bought $40,016 worth of shares (11,216 units at $3.57), increasing direct ownership by 2% to 468,626 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/26/25 5:01:54 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Agee Nancy H bought $69,000 worth of shares (15,000 units at $4.60), increasing direct ownership by 7% to 217,841 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/5/25 5:46:22 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Agee Nancy H bought $98,643 worth of shares (26,005 units at $3.79), increasing direct ownership by 15% to 202,841 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    8/29/25 4:21:18 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    SEC Filings

    View All

    SEC Form 144 filed by Precigen Inc.

    144 - PRECIGEN, INC. (0001356090) (Subject)

    9/29/25 4:12:32 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Precigen Inc.

    EFFECT - PRECIGEN, INC. (0001356090) (Filer)

    9/22/25 12:15:16 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Precigen Inc.

    SCHEDULE 13D/A - PRECIGEN, INC. (0001356090) (Subject)

    9/19/25 8:55:36 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Thomasian Harry Jr. bought $40,016 worth of shares (11,216 units at $3.57), increasing direct ownership by 2% to 468,626 units (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/26/25 5:01:54 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kirk Randal J converted options into 17,385,257 shares and sold $18,653,532 worth of shares (5,000,252 units at $3.73) (SEC Form 4)

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/19/25 8:46:14 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President and CEO Sabzevari Helen

    4 - PRECIGEN, INC. (0001356090) (Issuer)

    9/16/25 7:47:23 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    Leadership Updates

    Live Leadership Updates

    View All

    Precigen Reports First Quarter 2025 Financial Results and Business Updates

    PRGN-2012 has the potential to be the first- and best-in-class treatment for RRPCompany's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA target action date set for August 27, 2025RRP is a rare, debilitating chronic disease with approximately 27,000 adult patients in the US and more than 125,000 patients outside of the USCompany continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch Company and Recurrent Respiratory Papillomatosis Foundation to host the 2025 International RRP Awareness Day on June 11Cash, cash equivalents, and investments of $81.0 million as of March 31, 20

    5/14/25 4:05:00 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

    – International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury – GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovativ

    4/16/25 8:05:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

    –  Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis – GERMANTOWN, Md., July 23, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer. Mr. Tennant will be responsible for commercial strategy and execution across US and global markets. His initial focus will be on driving commercial readiness activities for the potential launch of the first- and best-in-class PRGN-2012 Aden

    7/23/24 8:01:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    Financials

    Live finance-specific insights

    View All

    Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

    PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with RRP PAPZIMEOS received full approval from the FDA for the treatment of adults with RRP; a confirmatory clinical trial is no longer required RRP is a rare, debilitating, and potentially life-threatening disease caused by chronic HPV 6 or HPV 11 infection, which results in recurrent benign tumors in the respiratory tract; RRP affects an estimated 27,000 adult patients in the USPAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy designed to generate an immune response directed against papilloma cells expressing HPV 6/11—the firs

    8/15/25 7:00:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

    GERMANTOWN, Md., March 13, 2025 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release full year 2024 financial results and provide business updates on Wednesday, March 19, 2025. The Company will host a conference call to discuss results that day at 4:30 PM ET. The conference call may be accessed by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (International). Participants are asked to dial in 10-15 minu

    3/13/25 8:05:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

    GERMANTOWN, Md., Dec. 27, 2024 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that it has entered into a securities purchase agreement for the sale of its 8.00% Series A Convertible Perpetual Preferred Stock (Preferred Stock) in a private placement. Precigen anticipates gross proceeds from the private placement of $79.0 million before deducting offering expenses. In addition, the investors will have rights to exercise warrants to purchase 52,666,669 shares of Precigen's common stock at an exercise price of $0.75 per share (Warrants). The offering

    12/27/24 9:00:00 AM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Precigen Inc.

    SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)

    8/13/24 4:05:10 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Precigen Inc. (Amendment)

    SC 13D/A - PRECIGEN, INC. (0001356090) (Subject)

    5/3/24 8:01:15 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Precigen Inc. (Amendment)

    SC 13G/A - PRECIGEN, INC. (0001356090) (Subject)

    2/27/24 1:48:40 PM ET
    $PGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care